408 related articles for article (PubMed ID: 31049758)
1. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV.
Akamatsu H; Ninomiya K; Kenmotsu H; Morise M; Daga H; Goto Y; Kozuki T; Miura S; Sasaki T; Tamiya A; Teraoka S; Tsubata Y; Yoshioka H; Hattori Y; Imamura CK; Katsuya Y; Matsui R; Minegishi Y; Mizugaki H; Nosaki K; Okuma Y; Sakamoto S; Sone T; Tanaka K; Umemura S; Yamanaka T; Amano S; Hasegawa K; Morita S; Nakajima K; Maemondo M; Seto T; Yamamoto N
Int J Clin Oncol; 2019 Jul; 24(7):731-770. PubMed ID: 31049758
[TBL] [Abstract][Full Text] [Related]
2. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
Hanna N; Johnson D; Temin S; Baker S; Brahmer J; Ellis PM; Giaccone G; Hesketh PJ; Jaiyesimi I; Leighl NB; Riely GJ; Schiller JH; Schneider BJ; Smith TJ; Tashbar J; Biermann WA; Masters G
J Clin Oncol; 2017 Oct; 35(30):3484-3515. PubMed ID: 28806116
[TBL] [Abstract][Full Text] [Related]
3. Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
Hanna NH; Schneider BJ; Temin S; Baker S; Brahmer J; Ellis PM; Gaspar LE; Haddad RY; Hesketh PJ; Jain D; Jaiyesimi I; Johnson DH; Leighl NB; Phillips T; Riely GJ; Robinson AG; Rosell R; Schiller JH; Singh N; Spigel DR; Stabler JO; Tashbar J; Masters G
J Clin Oncol; 2020 May; 38(14):1608-1632. PubMed ID: 31990617
[TBL] [Abstract][Full Text] [Related]
4. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
Hanna NH; Robinson AG; Temin S; Baker S; Brahmer JR; Ellis PM; Gaspar LE; Haddad RY; Hesketh PJ; Jain D; Jaiyesimi I; Johnson DH; Leighl NB; Moffitt PR; Phillips T; Riely GJ; Rosell R; Schiller JH; Schneider BJ; Singh N; Spigel DR; Tashbar J; Masters G
J Clin Oncol; 2021 Mar; 39(9):1040-1091. PubMed ID: 33591844
[TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
7. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.
Hanna N; Johnson D; Temin S; Masters G
J Oncol Pract; 2017 Dec; 13(12):832-837. PubMed ID: 28850309
[No Abstract] [Full Text] [Related]
8. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).
Brahmer JR; Govindan R; Anders RA; Antonia SJ; Sagorsky S; Davies MJ; Dubinett SM; Ferris A; Gandhi L; Garon EB; Hellmann MD; Hirsch FR; Malik S; Neal JW; Papadimitrakopoulou VA; Rimm DL; Schwartz LH; Sepesi B; Yeap BY; Rizvi NA; Herbst RS
J Immunother Cancer; 2018 Jul; 6(1):75. PubMed ID: 30012210
[TBL] [Abstract][Full Text] [Related]
9. Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3.
Jaiyesimi IA; Leighl NB; Ismaila N; Alluri K; Florez N; Gadgeel S; Masters G; Schenk EL; Schneider BJ; Sequist L; Singh N; Bazhenova L; Blanchard E; Freeman-Daily J; Furuya N; Halmos B; Azar IH; Kuruvilla S; Mullane M; Naidoo J; Reuss JE; Spigel DR; Owen DH; Patel JD
J Clin Oncol; 2024 Apr; 42(11):e23-e43. PubMed ID: 38417098
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic Body Radiotherapy for Early-Stage Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline.
Schneider BJ; Daly ME; Kennedy EB; Antonoff MB; Broderick S; Feldman J; Jolly S; Meyers B; Rocco G; Rusthoven C; Slotman BJ; Sterman DH; Stiles BM
J Clin Oncol; 2018 Mar; 36(7):710-719. PubMed ID: 29106810
[TBL] [Abstract][Full Text] [Related]
11. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
Masters GA; Temin S; Azzoli CG; Giaccone G; Baker S; Brahmer JR; Ellis PM; Gajra A; Rackear N; Schiller JH; Smith TJ; Strawn JR; Trent D; Johnson DH;
J Clin Oncol; 2015 Oct; 33(30):3488-515. PubMed ID: 26324367
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stages I to IIIA Resectable Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update Summary.
Kris MG; Gaspar LE; Chaft JE; Kennedy EB
J Oncol Pract; 2017 Jul; 13(7):449-451. PubMed ID: 28441082
[No Abstract] [Full Text] [Related]
13. Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update.
Kris MG; Gaspar LE; Chaft JE; Kennedy EB; Azzoli CG; Ellis PM; Lin SH; Pass HI; Seth R; Shepherd FA; Spigel DR; Strawn JR; Ung YC; Weyant M
J Clin Oncol; 2017 Sep; 35(25):2960-2974. PubMed ID: 28437162
[TBL] [Abstract][Full Text] [Related]
14. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3.
Jaiyesimi IA; Leighl NB; Ismaila N; Alluri K; Florez N; Gadgeel S; Masters G; Schenk EL; Schneider BJ; Sequist L; Singh N; Bazhenova L; Blanchard E; Freeman-Daily J; Furuya N; Halmos B; Azar IH; Kuruvilla S; Mullane M; Naidoo J; Reuss JE; Spigel DR; Owen DH; Patel JD
J Clin Oncol; 2024 Apr; 42(11):e1-e22. PubMed ID: 38417091
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Efficacy and Safety of Single and Double Immune Checkpoint Inhibitor-Based First-Line Treatments for Advanced Driver-Gene Wild-Type Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
Xu Q; Zhang X; Huang M; Dai X; Gao J; Li S; Sheng L; Huang K; Wang J; Liu L
Front Immunol; 2021; 12():731546. PubMed ID: 34484242
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer.
Puri S; Shafique M; Gray JE
Curr Treat Options Oncol; 2018 Jun; 19(8):39. PubMed ID: 29931587
[TBL] [Abstract][Full Text] [Related]
17. Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline.
Bezjak A; Temin S; Franklin G; Giaccone G; Govindan R; Johnson ML; Rimner A; Schneider BJ; Strawn J; Azzoli CG
J Clin Oncol; 2015 Jun; 33(18):2100-5. PubMed ID: 25944914
[TBL] [Abstract][Full Text] [Related]
18. Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline.
Singh N; Temin S; Baker S; Blanchard E; Brahmer JR; Celano P; Duma N; Ellis PM; Elkins IB; Haddad RY; Hesketh PJ; Jain D; Johnson DH; Leighl NB; Mamdani H; Masters G; Moffitt PR; Phillips T; Riely GJ; Robinson AG; Rosell R; Schiller JH; Schneider BJ; Spigel DR; Jaiyesimi IA
J Clin Oncol; 2022 Oct; 40(28):3323-3343. PubMed ID: 35816668
[TBL] [Abstract][Full Text] [Related]
19. Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis.
Zhou Y; Chen C; Zhang X; Fu S; Xue C; Ma Y; Fang W; Yang Y; Hou X; Huang Y; Zhao H; Hong S; Zhang L
J Immunother Cancer; 2018 Dec; 6(1):155. PubMed ID: 30577837
[TBL] [Abstract][Full Text] [Related]
20. Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines.
Passiglia F; Pilotto S; Facchinetti F; Bertolaccini L; Del Re M; Ferrara R; Franchina T; Malapelle U; Menis J; Passaro A; Ramella S; Rossi G; Trisolini R; Novello S
Crit Rev Oncol Hematol; 2020 Feb; 146():102858. PubMed ID: 31918343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
